Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
DR REDDYS LABORATORIES LTD (RDY) has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for QDENGA, Takeda’s dengue vaccine, in India’s private market. Dr. Reddy’s will exclusively distribute and promote QDENGA for pediatric and adult vaccination in the private market, while Takeda will retain commercialization rights in the public market, and will handle manufacturing and importation of the vaccine. The arrangement involves no upfront consideration or milestone payments; other commercial terms are confidential. QDENGA received marketing authorization from India’s Central Drugs Standard Control Organization in July 2026 for individuals aged 4–60 years and, subject to applicable local processes, is anticipated to be available in the first half of 2027. The collaboration aligns with Dr. Reddy’s strategy to strengthen its vaccines business in India and is positioned to support broader public-health efforts against dengue.
DR REDDYS LABORATORIES LTD (RDY) reports that the U.S. Food and Drug Administration completed a records assessment under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act at its API manufacturing facility, Industrias Químicas Falcón de México, S.A. de C.V., in Jiutepec, Morelos, Mexico. The assessment took place between July 17, 2026 and September 8, 2026. At the conclusion, the FDA issued a Form FDA 2953 with two observations, and the company states it will respond within the stipulated timeline.
DR REDDYS LABORATORIES LTD (RDY) reports as a foreign private issuer on Form 6-K that its management plans to participate in upcoming analyst and institutional investor meetings. The company will attend investor conferences organized by ICICI Securities on September 17, 2026 in Hyderabad and by Bank of America on September 24, 2026 via a virtual format.
Both meetings are scheduled as group meetings, with the ICICI Securities session from 12:30 to 13:30 IST and the Bank of America session from 14:00 to 15:00 IST. The company notes that this schedule may change due to exigencies on the part of investors or the company.
DR REDDYS LABORATORIES LTD (RDY) reports the allotment of 375 equity shares of face value Re.1 each on September 10, 2026, to employees exercising stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. These fully paid shares rank pari passu with existing equity shares.
Total issued shares after this allotment are 834,681,285, with total issued share capital of Rs. 834,681,285. The paid-up capital reflects 834,680,285 equity shares, with a difference of 1,000 shares due to forfeited shares from September 1988.
DR. REDDY’S LABORATORIES LIMITED (symbol RDY) reports the allotment of 4,110 equity shares of face value Re.1 each on August 26, 2026 to eligible employees following exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002. These fully paid shares are equity shares that rank pari passu with existing shares. After this issuance, total issued shares are 83,46,80,910 and total issued share capital is Rs. 83,46,80,910, while total paid-up capital is 83,46,79,910 equity shares of Re.1 each, aggregating to Rs. 83,46,79,910, reflecting 1,000 forfeited shares from September 1988.
Dr. Reddy’s Laboratories Limited reported the outcome of a United States Food & Drug Administration inspection at its active pharmaceutical ingredient manufacturing facility in Mirfield, West Yorkshire, United Kingdom. The inspection has been classified as “Voluntary Action Indicated (VAI)”, and the USFDA has concluded and officially closed the inspection under 21 CFR 20.64(d)(3). This indicates the facility remains under normal regulatory status with only voluntary corrective actions, if any, expected from the company.
Dr. Reddy’s Laboratories Limited reported that the United States Food & Drug Administration completed a GMP inspection of its formulations manufacturing facility FTO-3 in Bachupally, Hyderabad. The inspection took place from August 6, 2026 to August 14, 2026. Following the inspection, the company received a Form 483 with four observations, which it states will be addressed within the stipulated timeline.
Dr. Reddy’s Laboratories Limited reports that Mr. Deepak Sapra has resigned from his role as CEO, API and Services, and as a member of the company’s Senior Management Personnel to pursue opportunities outside the company. He will remain in employment and part of senior management until the close of business hours on November 12, 2026, providing transition support and handover of responsibilities.
The company states that the disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sapra’s resignation letter notes his association with Dr. Reddy’s for more than 23 years since 2003 and expresses gratitude for the learning, guidance and support during his tenure.
Dr. Reddy’s Laboratories Limited reported that it has terminated its agreement dated February 11, 2022 with Novartis India Limited covering the distribution and promotion of select brands in India. The termination is linked to a change in the controlling shareholding of Novartis India Limited.
Dr. Reddy’s stated that it will continue to commercialize the brands covered by this agreement in India until September 30, 2026, after which the existing arrangement will cease. No financial impact, volumes, or brand list are specified in the disclosure.
Dr. Reddy’s Laboratories received U.S. FDA approval for its rituximab biosimilar, a biosimilar to Rituxan (rituximab), for the U.S. market. The product was developed, manufactured and submitted by Dr. Reddy’s, and the approval followed a successful Pre-License Inspection at its biologics facility in Bachupally, Hyderabad.
Under an exclusive commercialization agreement, Fresenius Kabi will market the product in the United States, a key global pharmaceutical market. The rituximab biosimilar is already commercialized in India, the European Union, the United Kingdom and more than 25 emerging markets, with additional approvals in Switzerland and Canada, reinforcing Dr. Reddy’s strategy to expand its biosimilars portfolio in oncology and autoimmune diseases.